Randomized phase II study of clinical effects of ghrelin after esophagectomy with gastric tube reconstruction

Kazuyoshi Yamamoto, Shuji Takiguchi, Hiroshi Miyata, Shinichi Adachi, Yuichiro Hiura, Makoto Yamasaki, Kiyokazu Nakajima, Yoshiyuki Fujiwara, Masaki Mori, Kenji Kangawa, Yuichiro Doki

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Background: Ghrelin is a peptide hormone with pleiotropic functions including stimulation of growth hormone secretion and appetite, and its levels decrease after esophagectomy. The aim of this study was to evaluate whether exogenous ghrelin administration can meliorate the postoperative decrease of oral food intake and body weight, which are serious complications after esophagectomy. Methods: This prospective randomized, placebo-controlled, clinical trial assigned a total of 20 patients with thoracic esophageal cancer who underwent radical operation into either a ghrelin (n = 10) or placebo (n = 10) group. Synthetic human ghrelin (3 μg/kg) or 0.9% saline placebo was administered intravenously twice daily for 10 days from the day after the start of food intake. The primary end point was calories of food intake. Comparison of appetite and changes in weight and body composition were also made between the 2 groups. Results: Intake of food calories was greater in ghrelin group than placebo group (mean 874 vs 605 kcal per day; P = .015). The appetite score tended to be greater in ghrelin group than placebo group (P = .094). Loss of weight was less in ghrelin group (-1% vs -3%; P = .019) and this attenuation was due largely to a decrease of lean body weight loss (0% vs -4%; P = .012). No side effects were observed in either groups. Conclusion: These preliminary results suggest that administration of ghrelin after esophagectomy increased oral food intake and attenuated weight loss together with maintenance of lean body weight.

Original languageEnglish
Pages (from-to)31-38
Number of pages8
JournalSurgery
Volume148
Issue number1
DOIs
Publication statusPublished - Jul 1 2010
Externally publishedYes

Fingerprint

Ghrelin
Esophagectomy
Stomach
Eating
Placebos
Appetite
Weight Loss
Body Weight
Clinical Studies
Peptide Hormones
Esophageal Neoplasms
Body Composition
Growth Hormone
Thorax
Randomized Controlled Trials
Weights and Measures

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Yamamoto, K., Takiguchi, S., Miyata, H., Adachi, S., Hiura, Y., Yamasaki, M., ... Doki, Y. (2010). Randomized phase II study of clinical effects of ghrelin after esophagectomy with gastric tube reconstruction. Surgery, 148(1), 31-38. https://doi.org/10.1016/j.surg.2009.11.026

Randomized phase II study of clinical effects of ghrelin after esophagectomy with gastric tube reconstruction. / Yamamoto, Kazuyoshi; Takiguchi, Shuji; Miyata, Hiroshi; Adachi, Shinichi; Hiura, Yuichiro; Yamasaki, Makoto; Nakajima, Kiyokazu; Fujiwara, Yoshiyuki; Mori, Masaki; Kangawa, Kenji; Doki, Yuichiro.

In: Surgery, Vol. 148, No. 1, 01.07.2010, p. 31-38.

Research output: Contribution to journalArticle

Yamamoto, K, Takiguchi, S, Miyata, H, Adachi, S, Hiura, Y, Yamasaki, M, Nakajima, K, Fujiwara, Y, Mori, M, Kangawa, K & Doki, Y 2010, 'Randomized phase II study of clinical effects of ghrelin after esophagectomy with gastric tube reconstruction', Surgery, vol. 148, no. 1, pp. 31-38. https://doi.org/10.1016/j.surg.2009.11.026
Yamamoto, Kazuyoshi ; Takiguchi, Shuji ; Miyata, Hiroshi ; Adachi, Shinichi ; Hiura, Yuichiro ; Yamasaki, Makoto ; Nakajima, Kiyokazu ; Fujiwara, Yoshiyuki ; Mori, Masaki ; Kangawa, Kenji ; Doki, Yuichiro. / Randomized phase II study of clinical effects of ghrelin after esophagectomy with gastric tube reconstruction. In: Surgery. 2010 ; Vol. 148, No. 1. pp. 31-38.
@article{b4a535ae16ec429389f5dcc1b747d953,
title = "Randomized phase II study of clinical effects of ghrelin after esophagectomy with gastric tube reconstruction",
abstract = "Background: Ghrelin is a peptide hormone with pleiotropic functions including stimulation of growth hormone secretion and appetite, and its levels decrease after esophagectomy. The aim of this study was to evaluate whether exogenous ghrelin administration can meliorate the postoperative decrease of oral food intake and body weight, which are serious complications after esophagectomy. Methods: This prospective randomized, placebo-controlled, clinical trial assigned a total of 20 patients with thoracic esophageal cancer who underwent radical operation into either a ghrelin (n = 10) or placebo (n = 10) group. Synthetic human ghrelin (3 μg/kg) or 0.9{\%} saline placebo was administered intravenously twice daily for 10 days from the day after the start of food intake. The primary end point was calories of food intake. Comparison of appetite and changes in weight and body composition were also made between the 2 groups. Results: Intake of food calories was greater in ghrelin group than placebo group (mean 874 vs 605 kcal per day; P = .015). The appetite score tended to be greater in ghrelin group than placebo group (P = .094). Loss of weight was less in ghrelin group (-1{\%} vs -3{\%}; P = .019) and this attenuation was due largely to a decrease of lean body weight loss (0{\%} vs -4{\%}; P = .012). No side effects were observed in either groups. Conclusion: These preliminary results suggest that administration of ghrelin after esophagectomy increased oral food intake and attenuated weight loss together with maintenance of lean body weight.",
author = "Kazuyoshi Yamamoto and Shuji Takiguchi and Hiroshi Miyata and Shinichi Adachi and Yuichiro Hiura and Makoto Yamasaki and Kiyokazu Nakajima and Yoshiyuki Fujiwara and Masaki Mori and Kenji Kangawa and Yuichiro Doki",
year = "2010",
month = "7",
day = "1",
doi = "10.1016/j.surg.2009.11.026",
language = "English",
volume = "148",
pages = "31--38",
journal = "Surgery",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Randomized phase II study of clinical effects of ghrelin after esophagectomy with gastric tube reconstruction

AU - Yamamoto, Kazuyoshi

AU - Takiguchi, Shuji

AU - Miyata, Hiroshi

AU - Adachi, Shinichi

AU - Hiura, Yuichiro

AU - Yamasaki, Makoto

AU - Nakajima, Kiyokazu

AU - Fujiwara, Yoshiyuki

AU - Mori, Masaki

AU - Kangawa, Kenji

AU - Doki, Yuichiro

PY - 2010/7/1

Y1 - 2010/7/1

N2 - Background: Ghrelin is a peptide hormone with pleiotropic functions including stimulation of growth hormone secretion and appetite, and its levels decrease after esophagectomy. The aim of this study was to evaluate whether exogenous ghrelin administration can meliorate the postoperative decrease of oral food intake and body weight, which are serious complications after esophagectomy. Methods: This prospective randomized, placebo-controlled, clinical trial assigned a total of 20 patients with thoracic esophageal cancer who underwent radical operation into either a ghrelin (n = 10) or placebo (n = 10) group. Synthetic human ghrelin (3 μg/kg) or 0.9% saline placebo was administered intravenously twice daily for 10 days from the day after the start of food intake. The primary end point was calories of food intake. Comparison of appetite and changes in weight and body composition were also made between the 2 groups. Results: Intake of food calories was greater in ghrelin group than placebo group (mean 874 vs 605 kcal per day; P = .015). The appetite score tended to be greater in ghrelin group than placebo group (P = .094). Loss of weight was less in ghrelin group (-1% vs -3%; P = .019) and this attenuation was due largely to a decrease of lean body weight loss (0% vs -4%; P = .012). No side effects were observed in either groups. Conclusion: These preliminary results suggest that administration of ghrelin after esophagectomy increased oral food intake and attenuated weight loss together with maintenance of lean body weight.

AB - Background: Ghrelin is a peptide hormone with pleiotropic functions including stimulation of growth hormone secretion and appetite, and its levels decrease after esophagectomy. The aim of this study was to evaluate whether exogenous ghrelin administration can meliorate the postoperative decrease of oral food intake and body weight, which are serious complications after esophagectomy. Methods: This prospective randomized, placebo-controlled, clinical trial assigned a total of 20 patients with thoracic esophageal cancer who underwent radical operation into either a ghrelin (n = 10) or placebo (n = 10) group. Synthetic human ghrelin (3 μg/kg) or 0.9% saline placebo was administered intravenously twice daily for 10 days from the day after the start of food intake. The primary end point was calories of food intake. Comparison of appetite and changes in weight and body composition were also made between the 2 groups. Results: Intake of food calories was greater in ghrelin group than placebo group (mean 874 vs 605 kcal per day; P = .015). The appetite score tended to be greater in ghrelin group than placebo group (P = .094). Loss of weight was less in ghrelin group (-1% vs -3%; P = .019) and this attenuation was due largely to a decrease of lean body weight loss (0% vs -4%; P = .012). No side effects were observed in either groups. Conclusion: These preliminary results suggest that administration of ghrelin after esophagectomy increased oral food intake and attenuated weight loss together with maintenance of lean body weight.

UR - http://www.scopus.com/inward/record.url?scp=77953287167&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953287167&partnerID=8YFLogxK

U2 - 10.1016/j.surg.2009.11.026

DO - 10.1016/j.surg.2009.11.026

M3 - Article

C2 - 20096432

AN - SCOPUS:77953287167

VL - 148

SP - 31

EP - 38

JO - Surgery

JF - Surgery

SN - 0039-6060

IS - 1

ER -